Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2021; 121(04): 518-528
DOI: 10.1055/s-0040-1717115
Stroke, Systemic or Venous Thromboembolism

Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES

Alexander P. Benz 
1   Population Health Research Institute, Hamilton, Ontario, Canada
,
John W. Eikelboom
1   Population Health Research Institute, Hamilton, Ontario, Canada
,
Salim Yusuf
1   Population Health Research Institute, Hamilton, Ontario, Canada
,
Stefan H. Hohnloser
2   Division Clinical Electrophysiology, Department of Cardiology, Johann Wolfgang Goethe University, Frankfurt, Germany
,
Anja Kahl
3   Bristol-Myers Squibb, Lawrenceville, New Jersey, Unites States
,
Heather Beresh
1   Population Health Research Institute, Hamilton, Ontario, Canada
,
Kumar Balasubramanian
1   Population Health Research Institute, Hamilton, Ontario, Canada
,
Jeff S. Healey
1   Population Health Research Institute, Hamilton, Ontario, Canada
,
Stuart J. Connolly
1   Population Health Research Institute, Hamilton, Ontario, Canada
› Author Affiliations Funding AVERROES and its open-label extension were funded by Bristol-Myers Squibb and Pfizer. A.P.B. reports a personal research grant from the German Heart Foundation (Deutsche Herzstiftung e.V.).
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background AVERROES, a randomized controlled trial in high-risk patients with atrial fibrillation, unsuitable for vitamin K antagonist therapy, demonstrated efficacy and safety of apixaban compared with aspirin. At the conclusion of the double-blind phase, an open-label extension was initiated to allow study participants to receive apixaban until it became locally available. This study reports outcomes of patients on apixaban during the open-label extension.

Methods Rates of stroke or systemic embolism, hemorrhagic stroke, major bleeding, and other outcomes during the open-label extension are reported.

Results Of the 5,599 participants enrolled in AVERROES, 3,275 (58.5%) received apixaban during the open-label extension. Median (interquartile range) follow-up in the open-label extension was 3.0 (2.5–3.5) years. The rate of stroke or systemic embolism during the open-label extension was 1.0% per year, and the annual rates of hemorrhagic stroke and major bleeding were 0.3 and 1.2%, respectively. After adjustment for imbalances in patient variables, event rates in patients on apixaban during the open-label extension were similar to those of patients receiving apixaban during AVERROES. Additional analyses in all patients who received apixaban, at any time from the start of AVERROES to the end of the open-label extension, were performed. This cohort (n = 4,414) showed annual event rates of 1.1% for stroke or systemic embolism, 0.3% for hemorrhagic stroke, and 1.2% for major bleeding.

Conclusion During the open-label extension, annual rates of stroke or systemic embolism, hemorrhagic stroke, and major bleeding remained as low as those observed during apixaban treatment in AVERROES. These data support the long-term efficacy and safety of apixaban in patients with atrial fibrillation.

Keywords

apixaban - extension - atrial fibrillation - stroke - bleeding

Supplementary Material



Publication History

Received: 20 February 2020

Accepted: 18 August 2020

Article published online:
04 October 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Comment to this article:

Long-Term Effects of Apixaban Confirmed in the Open-Label Extension of AVERROES TrialThromb Haemost 2021; 121(04): 405-407
DOI: 10.1055/a-1367-0184

 

  • References

  • 1 Chugh SS, Havmoeller R, Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129 (08) 837-847
    CrossrefPubMedGoogle Scholar
  • 2 Go AS, Hylek EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001; 285 (18) 2370-2375
    CrossrefPubMedGoogle Scholar
  • 3 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22 (08) 983-988
    CrossrefPubMedGoogle Scholar
  • 4 Healey JS, Oldgren J, Ezekowitz M. et al. RE-LY Atrial Fibrillation Registry and Cohort Study Investigators. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet 2016; 388 (10050): 1161-1169
    CrossrefPubMedGoogle Scholar
  • 5 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
    CrossrefPubMedGoogle Scholar
  • 6 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
    CrossrefPubMedGoogle Scholar
  • 7 Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and safety of non-vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost 2018; 118 (03) 526-538
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Connolly SJ, Eikelboom J, Joyner C. et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
    CrossrefPubMedGoogle Scholar
  • 9 Eikelboom JW, O'Donnell M, Yusuf S. et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010; 159 (03) 348-353.e1
    CrossrefPubMedGoogle Scholar
  • 10 Granger CB, Alexander JH, McMurray JJ. et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 11 January CT, Wann LS, Alpert JS. et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64 (21) e1-e76
    CrossrefPubMedGoogle Scholar
  • 12 Kirchhof P, Benussi S, Kotecha D. et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedGoogle Scholar
  • 13 Granger CB, Lopes RD, Hanna M. et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2015; 169 (01) 25-30
    CrossrefPubMedGoogle Scholar
  • 14 Mahaffey KW, Hellkamp AS, Patel MR. et al. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circ Cardiovasc Qual Outcomes 2013; 6 (04) 470-478
    CrossrefPubMedGoogle Scholar
  • 15 Ruff CT, Giugliano RP, Braunwald E. et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2014; 64 (06) 576-584
    CrossrefPubMedGoogle Scholar